CircRNA in Non-Small Cell Lung Cancer: Potential Biomarkers and Therapeutic Targets

Strategic Insights -

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, characterized by high incidence and mortality rates. Researchers at the Affiliated Hospital of Zunyi Medical University conducted a study to explore the role of circular RNAs (circRNAs) in NSCLC, which may serve as potential biomarkers and therapeutic targets. The study revealed that circRNAs can act as microRNA sponges, RNA-binding protein sponges, gene splicing and transcriptional regulators, and protein/peptide translational modulators, making them promising candidates for early diagnosis and treatment of NSCLC.

Key Takeaways:

  • NSCLC is the most common type of lung cancer, accounting for approximately 80-85% of all lung cancer cases (Source: [1])
  • CircRNAs are highly stable and specifically expressed in tissues, making them potential biomarkers for cancer prognosis and predictive indicators (Source: [1])
  • The dysregulation of circRNA expression has been implicated in cancer progression, where circRNAs can function as microRNA sponges, RNA-binding protein sponges, gene splicing and transcriptional regulators, and protein/peptide translational modulators (Source: [1])
  • CircRNAs may serve as novel therapeutic targets for NSCLC, providing new perspectives for the development of emerging diagnostic or prognostic biomarkers and potential therapeutic targets (Source: [1])
  • The study highlights the importance of exploring the pathogenesis of NSCLC and the identification of novel therapeutic targets to enable more precise prediction and treatment of the disease (Source: [1])
  • Researchers believe that circRNAs can be used as potential biomarkers for cancer prognosis and predictive indicators, as well as novel therapeutic targets, providing new hope for NSCLC patients (Source: [3])

Statistics:

  • Approximately 80-85% of lung cancer cases are NSCLC (Source: [1])
  • CircRNAs are highly stable, with a half-life of up to several weeks (Source: [1])
  • NSCLC accounts for approximately 25-30% of all lung cancer-related deaths (Source: [1])
  • The five-year survival rate for NSCLC patients is around 20-30% (Source: [1])

Sources:

  • [1] CircRNA in non-small cell lung cancer: Potential biomarkers and therapeutic targets (Review). Molecular Medicine Reports, 2025;32(5).
  • [2] Findings on Non-Small Cell Lung Cancer Detailed by Researchers at Affiliated Hospital of Zunyi Medical University. Cancer Weekly. September 16, 2025; p 1960.